

Reference	Reason for exclusion
Allison C, Fraser J. Grazax: an oral vaccine for the treatment of grass pollen allergy (hay fever). <i>Issues Emerg Health Tech</i> 2007; 107 :1–4	Not EE, does not report relevant information
Alvarez-Cuesta E, Gonzelez-Mancebo E. Immunotherapy in bronchial asthma. <i>Curr Opin Pulm Med</i> 2000; 6 :50–4	Not EE, does not report relevant information
Bachert CJ, Jorissen M, Bertrand B, KhattaeV N, Bousquet J. Allergic Rhinitis and its Impact on Asthma update (ARIA 2008). The Belgian perspective', <i>B-ENT</i> 2008; 4 :253–7	No relevant information reported
Baiardini I, Braido F, Tarantini F, Porcu A, Bonini S, Bousquet PJ, <i>et al.</i> , GA2LEN. ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN review. <i>Allergy</i> 2008; 63 :660–9	No relevant information reported
Barnes PJ. Is immunotherapy for asthma worthwhile? <i>N Engl J Med</i> 1996; 334 :531–2	Editorial, No relevant information reported
Belliveau PP. Omalizumab: A monoclonal anti-IgE antibody. <i>Medsc Gen Med</i> 2005; 7 :27	No relevant information reported
Bergmann KC, Wolf H, Schnitker J, <i>et al.</i> Quality of life and compliance of patients treated with specific immunotherapy using grass and rye allergens (LQC study). <i>Allergo J</i> 2000; 9 :480–8	No relevant information reported
Bernstein JA. Cost-benefit analysis for allergen immunotherapy. <i>Immunol Allergy Clin</i> 2000; 20 :593–608	No relevant information reported
Bernstein JA. Pharmacoeconomic considerations for allergen immunotherapy. <i>Clin Allergy Immunol</i> 2004; 8 :151–64	Not EE, does not report relevant information
Berto P, Frati F, Incorvaia C, Cadario G, Contiguglia R, Di Gioacchino M, <i>et al.</i> Comparison of costs of sublingual immunotherapy and drug treatment in grass-pollen induced allergy: results from the SIMAP database study. <i>Curr Med Res Opin</i> 2008; 24 :261–6	Not EE, does not report relevant information
Büchner KS. An economic evaluation of a specific immunotherapeutic drug. Summary of results from an Infratest Suisse study, conducted for the Federal Republic of Germany (West). <i>Allergo J</i> 1995; 4 :156–63	No relevant information reported
Canonica GW, Passalacqua G. Sublingual immunotherapy in the treatment of adult allergic rhinitis patients. <i>Allergy</i> 2006; 61 :20–3	Not a review of EEs
Canonica GW, Passalacqua P. Disease-modifying effect and economic implications of sublingual immunotherapy. <i>J Allergy Clin Immunol</i> 2011; 127 :44–5	Commentary, does not report relevant information
Carr,WW, Nelson MR, Hadley JA. Managing rhinitis: Strategies for improved patient outcomes. <i>Allergy Asthma Proc</i> 2008; 29 :349–57	No relevant information reported
Compalati E, Penagos E. Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. <i>Ann Allergy Asthma Immunol</i> 2009; 102 :22–8.	No relevant information reported
Cox L. Sublingual immunotherapy and allergic rhinitis. <i>Current Allergy Asthma Rep</i> 2008; 8 :102–10	Not a review of EEs.
del Cuvillo A, Montoro J, Bartra J, Valero A, Ferrer M, Jauregui I, <i>et al.</i> Validation of ARIA duration and severity classifications in Spanish allergic rhinitis patients: The ADRIAL cohort study. <i>Rhinology</i> 2010; 48 :201–5	No relevant information reported
Douglass JA, Thien FC, O'Hehir RE. Immunotherapy in asthma. <i>Thorax</i> 1997; 52 :S22–9	No relevant information reported
Fell WR, Mabry RL, Mabry C. Quality of life analysis of patients undergoing immunotherapy for allergic rhinitis. <i>Ear Nose Throat J</i> 1997; 76 :528–32	No relevant information reported

Reference	Reason for exclusion
Goksel O, Sin B, Aydy'n O, Mungan D, Demirel Y, Pinar M, et al. Grass pollen preseasonal immunotherapy: the effect on direct medical cost and quality of life. <i>Allergy</i> 2009; 64 :458 (poster 1200)	Conference poster, no relevant information reported
Goldman M. Sublingual immunotherapy: The quest for innovative adjuvants. <i>Clin Exp Allergy</i> 2008; 38 :1705–6	Editorial, no relevant information reported
Goldschmidt O. Treatment of allergic rhinoconjunctivitis seen from health economical point of view. <i>Allergologie</i> 1998; 21 :S68–72	No relevant information reported
Greiner AN. Allergic rhinitis: impact of the disease and considerations for management. <i>Med Clin North Am</i> 2006; 90 :17–38	No relevant information reported
Hadley JA. Overview of otolaryngic allergy management: An eclectic and cost- effective approach. <i>Otolaryngol Clin North Am</i> 1998; 31 :69–82	Not immunotherapy
Hankin CS, Cox L, Lang D, Levin A, Gross G, Eavy G, et al. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. <i>J Allergy Clin Immunol</i> 2008; 121 :227–32	Not EE, does not report relevant information
Hankin CS, Cox L, Leatherman B, Lang D, Gross G, Fass P, et al. Allergy immunotherapy confers significant health care cost savings within 3 months of initiation: a matched retrospective cohort study of Medicaid-enrolled children newly diagnosed with allergic rhinitis. <i>Value Health</i> 2009; 12 :A122	Conference proceeding, does not report any relevant information
Hankin CS, Cox L, Lang D, Bronstone A, Fass P, Leatherman B, et al. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. <i>Ann Allergy Asthma Immunol</i> 2010; 104 :79–85	Not EE, does not report relevant information
Hankin CS, Cox L, Lang D, Bronston A, Fass P, Leatherman B, et al. 2011, Does allergen-specific immunotherapy reduce the risk, reverse, and/or mitigate asthma in children with allergic rhinitis? The pediatric improved access to allergen-specific immunotherapy - asthma incidence rates among Medicaid enrollees (pediatric-IMAGINE-AIRE) study, funded by the Joint Council of Allergy, Asthma and Immunology. <i>J Allergy Clin Immunol</i> 2011; 127 :AB73	Conference proceeding, does not report any relevant information
Incorvaia C, Agostinis F, Amoroso S, Ariano R, Barbato A, Bassi M, et al. Pharmacoeconomics of subcutaneous allergen immunotherapy. <i>Eur Ann Allergy Clin Immunol</i> 2007; 39 :17–20	Not EE, does not report relevant information
Kay AB, Lessof MH. Allergy: Conventional and alternative concepts. A report of the Royal College of Physicians Committee on Clinical Immunology and Allergy. <i>Clin Exp Allergy</i> 1992; 22 :1–44.	No relevant information reported
Kozma CM, Sadik MK, Watrous ML. Economic outcomes for the treatment of allergic rhinitis. <i>Pharmacoeconomics</i> 1996; 10 :4–13	No relevant information reported
Lockey RF, Hankin CS. Health economics of allergen-specific immunotherapy in the United States. <i>J Allergy Clin Immunol</i> 2011; 127 :39–43	Editorial, no relevant information reported
McCrory DC, Williams JW, Dolor RJ, Gray RN, Kolimaga JT, Reed S, et al. Management of allergic rhinitis in the working-age population. <i>Evidence Report: Technology Assessment (Summary)</i> 2003; 67 :1–4	No relevant information reported
McEwen LM. Immunotherapy and hayfever. <i>BMJ</i> 1991; 302 :530–1	Correspondence, no relevant information reported
Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. <i>Allergy</i> 1988; 43 :523–9	No relevant information reported
Nalebuff, D. J. PRIST, RAST, and beyond. Diagnosis and therapy. <i>Otolaryngol Clin North Am</i> 1985; 18 :725–44	Not immunotherapy
Nash DB, Sullivan SD, Mackowiak J. Optimizing quality of care and cost effectiveness in treating allergic rhinitis in a managed care setting. <i>Am J Manag Care</i> 2000; 6 :S3–15	No relevant information reported
Passalacqua G, Guerra L, Fumagalli F, Compalati E, Canonica GW. An update on sublingual immunotherapy. <i>Allergy and Clinical Immunology International</i> 2005; 17 :181–5	No relevant information reported

Reference	Reason for exclusion
Passalacqua G, Guerra L, Pasquali M, Canonica GW. Non-injection routes for allergen immunotherapy: Focus on sublingual immunotherapy. <i>Inflamm Allergy Drug Targets</i> 2006; 5 :43–51	No relevant information reported
Poulsen PB, Pedersen KM, Christensen J, Vestenbaek U. Economic evaluation of a tablet-based vaccination against hay fever in Denmark. <i>Ugeskrift Laeger</i> 2008; 170 :138–42	Data reported in Bachert 2007 (included in review)
Reed SD, Lee TA, McCrory DC. The economic burden of allergic rhinitis: a critical evaluation of the literature. <i>Pharmacoeconomics</i> 2004; 22 :345–61	No relevant information reported
Sanico AM. Latest developments in the management of allergic rhinitis. <i>Clin Rev Allergy Immunol</i> 2004; 27 :181–9	No relevant information reported
Schafer T, Riehle A, Wichmann HE, Ring J. Alternative medicine in allergies: prevalence, patterns of use, and costs. <i>Allergy</i> 2002; 57 :694–700	Not immunotherapy
Tamayama K, Hoshi SL, Kondo M, Okubo I. Cost-effectiveness analysis of pre-seasonal medication for cedar pollinosis in Japan. <i>Yakugaku Zasshi</i> 2010; 130 :1725–36	Not immunotherapy
Thomas, M. Allergic rhinitis: evidence for impact on asthma. <i>BMC Pulm Med</i> 2006; 6 :S4	Not a review of EEs
Tripathi A, Patterson R. Impact of allergic rhinitis treatment on quality of life. <i>Pharmacoeconomics</i> 2001; 19 :891–9	No relevant information reported
Wang ZH, Hankin CS, Cox L, Bronstone A. Allergen immunotherapy significantly reduces healthcare costs among US adults with allergic rhinitis: a retrospective matched cohort study Jointly Funded by the AAAAI and ACAAI. <i>J Allergy Clin Immunol</i> 2011; 127 :AB150	Conference proceeding, does not report any relevant information
Weiner JM. Allergen injection immunotherapy. <i>Med J Aust</i> 2006; 185 :234	No relevant information reported
Weiss KB, Haus M, Ikura Y. The costs of allergy and asthma and the potential benefit of prevention strategies. <i>Allergy</i> 2000; 55 :1083–4	No relevant information reported
Whitehead S, Taylor MJ, Christensen J. An economic evaluation of Grazax for the treatment of grass pollen induced rhinoconjunctivitis in children. <i>Value Health</i> 2009; 12 :A125 (PRS 26)	Conference proceeding, does not report any relevant information
Yilmaz M, Bingol G, Altintas D, Kendirli SG. Effect of SIT on quality of life. <i>Allergy</i> 2000; 55 :302	No relevant information reported
Yuta A, Miyamoto Y, Hattori R, Ogihara H, Takeuchi K, Majima Y. The influence of medical economy from the aspect of medical direct costs by a difference of the number of the pollen scattering on an allergen-specific immunotherapy for Japanese cedar pollinosis. <i>Jpn J Allergol</i> 2007; 56 :1366–71	Not EE, does not report relevant information

Full text not obtainable (British Library unable to supply at the time of ordering)

Blaiss MS. Cost-effectiveness of H1-antihistamines. <i>Clin Allergy Immunol</i> 2002; 17 :319–36
Grevers G. Rising prevalence, high costs. Hay fever remains a challenge. <i>MMW Fortsch Med</i> 2008; 150 :28
Pedersen KM. Economic evaluation of new medicines: when safety and efficacy are not enough. <i>Drugs Today</i> 2008; 44 :69–71
Pruzinec P. Economical evaluation of the allergen vaccination profit comparing to the symptomatic therapy of allergic diseases. <i>Klin Imunol Alergol</i> 2003; 13 :25–7
Scadding GK. Hay fever and asthma: are we failing our patients? <i>Drugs Today</i> 2008; 44 :19–24
Solari JE, Loo J, Felices A, Casas J. Immunotherapy for patients with persistent allergic rhinitis unsatisfied with free chronic pharmacotherapy. <i>Allergol Immunopathol</i> 2006; 34 :102–6
Warner-Klein MK. Sublingual immunotherapy of allergic diseases. <i>Expert Opin Drug Deliv</i> 2006; 3 :599–612

Identified after report completed

Hagen A, Gorenoi V, Schönermark MP. *Spezifische Immuntherapie (SIT) zur Behandlung der allergischen Rhinitis*. Köln, Germany: Deutsche Agentur für HTA des Deutschen Instituts für Medizinische Dokumentation und Information; 2010
